OneSource Specialty Pharma Shares Plunge 18% After Weak Q3 Performance

Shares of OneSource Specialty Pharma Ltd. plunged sharply on Tuesday after the company reported weak third-quarter financial results. The stock dropped as low as ₹1,164 on the BSE, down nearly 18% from the previous close, reflecting heavy selling pressure amid disappointing earnings and revenue trends. The question is why the company reported a loss?

Q3FY26 Financial Performance

The net loss of OneSource Specialty Pharma was ₹47 crore in Q3FY26, which is a major drawback from the previous year, where the company recorded a profit in the amount of ₹67. Revenue from operations fell sharply, dropping about 26% year-on-year to ₹290 crore from roughly ₹393 crore in the same period of the previous fiscal.

The decline in earnings and turnover was primarily due to delays in regulatory approvals for key products, most notably semaglutide in Canada, which adversely affected sales recognition and margins.

The performance in terms of operation was greatly affected and worsened in the quarter. EBITDA (earnings before interest, tax, depreciation and amortisation) decreased drastically to ₹17 crore, which is an 88% decrease as compared to ₹142 crore of Q3FY25.

Margins also compressed to 6%, down from 36% in the year-ago quarter, a decline of 3,018 basis points. One basis point equals 0.01%.

What Does the Management Say About the Results?

Commenting on the quarterly performance, Neeraj Sharma, CEO and Managing Director of OneSource Specialty Pharma, said the December quarter was subdued largely due to delays in customer approvals in Canada, which extended the transition from the MSA (Master Services Agreement) to the CSA (Commercial Supply Agreement) phase.

He also added that underlying demand remains intact, with the company’s order book continuing to trend upward.

Sharma also highlighted traction in the company’s biologics segment, noting that OneSource has onboarded another global biosimilar player and that the biologics pipeline is currently at a historic high, reflecting growing customer interest.

Despite the weak quarterly performance, OneSource Specialty Pharma reaffirmed its FY28 guidance. The company said it continues to target organic revenue of $400 million, with the potential to scale this up to $500 million, including the proposed acquisition.

Management also maintained its EBITDA margin guidance at 40%, indicating confidence in operating leverage as revenues normalise. In addition, the company reiterated its intention to keep net debt to EBITDA below 1.5 times.

What Does the Quarter Signal Going Ahead?

The December quarter reflected lower revenue and profitability for OneSource Specialty Pharma, driven primarily by delays in customer approvals in Canada and the resulting lag in transition from the MSA to the CSA phase. This led to a sharp contraction in EBITDA and margins due to the company’s fixed cost structure.

At the same time, the company has reiterated its FY28 guidance on revenue, margins and leverage, while highlighting an expanding order book and continued customer onboarding in its biologics segment. Going forward, investors should monitor regulatory approvals, commercialisation timelines, and the execution of the proposed acquisition, which will remain central to assessing quarterly performance trends.

Source

Economic Times

Business Standard